ReviewFrontiers in nutrition2025
n-3 PUFA-supplemented perioperative immunonutrition on postoperative outcomes in gastric cancer: a systematic review and meta-analysis.
Review in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the impact of perioperative immunonutritional regimens that included n-3 polyunsaturated fatty acids (n-3 PUFAs)-ranging from n-3 PUFA monotherapy to complex formulas combined with other immunonutrients-on postoperative outcomes in gastric cancer patients. Background: Although preventing postoperative complications is crucial for gastric cancer patients, consensus is lacking on the efficacy and optimal timing of administration of perioperative immunonutrition supplemented with n-3 PUFAs. Methods: We systematically searched PubMed, Embase, Web of Science, and the Cochrane Library for randomized controlled trials (RCTs) evaluating perioperative immunonutrition with n-3 PUFAs in gastric cancer surgery patients. Manual searches of reference lists were also conducted. The primary endpoint was total postoperative complications. Secondary endpoints included immune function [CD4+ T lymphocytes (CD4+ cells), CD8+ T lymphocytes (CD8+ cells), CD4+/CD8+ ratio, total lymphocytes, immunoglobulins IgA, IgG, IgM], nutritional status (transferrin, albumin, prealbumin), inflammatory markers (IL-6, TNF-α, CRP), and recovery indices (time to first flatus, length of hospital stay). Data were analyzed using RevMan v5.3 with a random-effect model. Results: Sixteen RCTs involving 1,642 patients were included. The meta-analysis demonstrated that perioperative n-3 PUFA supplementation significantly reduced the overall incidence of postoperative complications and promoted earlier recovery, as evidenced by a shortened time to first flatus and a reduced length of hospital stay. Furthermore, the n-3 PUFA group showed significant improvements in immunological (CD4+ T cell (%), CD4+/CD8+ ratio, total lymphocytes, IgA, IgG), inflammatory (IL-6, TNF-α, CRP), and nutritional (prealbumin) parameters. However, no significant differences were observed in CD8+ T cell (%), IgM, transferrin, or albumin levels between groups. Conclusion: The perioperative application of immunonutrition containing n-3 PUFAs can reduce the incidence of postoperative complications in patients with gastric cancer, improve immune function and nutritional status, mitigate inflammatory responses, and promote early postoperative recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.